'Aam Logon Ki Keemat Par Peteint Naheen

Business »

'Aam Logon Ki Keemat Par Peteint Naheen

India ke faurmar peteint kantrolar general si chandrashekharan peteint se judi khabaron par kareebi najar banaae hue hain. Unka aisa karna laajimi hai, kyonki jab pehli baar novaartis ke peteint klem ko khaarij kiya gaya tha, tab vah peteint office ke head the. Unhonne Indian peteint law ke aham sekshan 3(di) par soma das se baatcheet ki: Kya aap bata sakte hain ki India ke peteint rijeem ke liye 3(di) sekshan aham kyon hai? Sekshan 3(di) mahatvapoorn hai, kyonki sarkaar par yah pakka karne ki samvaidhaanik jimmedaari hai ki desh ke har naagrik ko helthakeyar ki suvidha mil sake. Ise kisi ek company ka ekaadhikaar rokane ke liye banaaya gaya hai. Ismein do rai naheen hai ki yah kaanoon trips (trade-rileted esapekts of intalekchual prauparti raaits) jaise hamaari international javaabadehi ke mutaabik hai. Pablik helth ke liye yah kaafi aham hathiyaar hai aur ismein badlaav ki jaroorat naheen hai. Inovetar pharma companiyon ka aarop hai ki inoveshan rokane vaale klauj se inoveshan ko nuksaan hota hai. Aise mein India kabhi bhi 3(di) jaise klauj ke saath aaraendadi ka aham kendra naheen ban sakta. Yah galat soch hai. Kisne kaha ki inkreemeintal inoveshan ko kaanoon protekt naheen karta. Novaartis maamale mein glaaivek ki eplikeshan mein jo daava kiya gaya tha, us par proses peteint diya gaya tha. Haalaanki, agar product ki kshamata mein ijaafa naheen hota hai, to vah 3(di) test mein peteint adhikaar banaae rakhane mein asafal ho jaaega. Main aise kai maamalon ka havaala day sakta hoon, jahaan Indian peteint office ne inkreemeintal inoveshans ke liye peteint graant kiya hai. Emaenasi agar 3(di) ki vajah se nai davaaen launch naheen kareingi, to kya India ko nuksaan naheen hoga? Aisa naheen hai. Hamaari jenerik industry bahut majaboot hai. Desh ki kai top pharma companiyaan bade paimaane par inavest kar rahi hain aur jenerik aaraendadi segameint mein jabaradast kaam kar rahi hain. Ve dava banaane ke liye naya proses khoj rahi hain. Mujhe bharosa hai ki Indian companiyaan nai davaaon ke mainyufaikcharing proses aur nae pharma kanpojeeshan lekar aaengi. Yahaan tak ki agar emaenasi apni davaaen Indian market mein naheen bhi utaarati hain, to Indian companiyaan iski kami mahasoos naheen hone deingi. Main samajhta hoon ki companiyon ko inavestameint par jyaada return haasil karne ki anumati milni chaahiye, lekin yah aam logon ki keemat par naheen hona chaahiye. Kya 3( di ) mein kisi tarah ke sanshodhan ki jaroorat hai ? Naheen , mujhe lagta hai ki ise jo sochakar banaaya gaya tha , yah vah kaam kar raha hai.

'Aam Logon Ki Keemat Par Peteint Naheen https://www.angrejinews.com/pic/4366